Skip to main content
. Author manuscript; available in PMC: 2022 Mar 4.
Published in final edited form as: Clin Cancer Res. 2021 Feb 10;27(11):3190–3200. doi: 10.1158/1078-0432.CCR-20-3363

Figure 3. MEKi/FAKi combination induces apoptosis and reduces UM melanosphere formation.

Figure 3.

(A) FACS analysis of cells positive for Annexin V was used to assess the apoptotic response to trametinib (10 nM), VS-4718 (1 μM), and their combination after 24 h of treatment. (B) Immunoblot showing cleaved-PARP, pFAK (pY-397) and pERK levels upon treatment with vehicle, trametinib (10 nM), VS-4718 (1 μM) or trametinib+VS-4718 for 48 hours in UM cells. (C) Left, OMM1.3 melanospheres formation after treatment with vehicle (control), trametinib (10 nM), VS-4718 (1 μM) or trametinib+VS-4718 for 3 weeks. Right, Representative spheres (A and C) Data shown represent the mean ± SEM of three independent experiments. ***p<0.001; **p< 0.01; n.s. not significant.